**Table S1: Confirming and refuting references used to calculate the R-factor.**

**Ward et al 2010**

**Confirming:**

([Andersson et al., 2011](#_ENREF_1); [Carbonneau et al., 2016](#_ENREF_2); [Chen et al., 2013](#_ENREF_3); [DiNardo et al., 2013](#_ENREF_4); [Figueroa et al., 2010](#_ENREF_5); [Gross et al., 2010](#_ENREF_6); [Janin et al., 2014](#_ENREF_7); [Jin et al., 2011](#_ENREF_8); [Kingsbury, Shamaprasad, Billmyre, Heitman, & Cardenas, 2016](#_ENREF_9); [Lemonnier et al., 2016](#_ENREF_10); [Leonardi, Subramanian, Jackowski, & Rock, 2012](#_ENREF_11); [Li et al., 2013](#_ENREF_12); [Reitman, Sinenko, Spana, & Yan, 2015](#_ENREF_13); [Robinson et al., 2016](#_ENREF_14); [Sellner et al., 2010](#_ENREF_15); [Showalter et al., 2017](#_ENREF_16); [Wen et al., 2015](#_ENREF_17))

Andersson, A. K., Miller, D. W., Lynch, J. A., Lemoff, A. S., Cai, Z., Pounds, S. B., . . . Downing, J. R. (2011). IDH1 and IDH2 mutations in pediatric acute leukemia. *Leukemia, 25*(10), 1570-1577. doi: 10.1038/leu.2011.133

Carbonneau, M., Gagne, L. M., Lalonde, M. E., Germain, M. A., Motorina, A., Guiot, M. C., . . . Mallette, F. A. (2016). The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway. *Nature Communications, 7*. doi: 10.1038/ncomms12700

Chen, C., Liu, Y., Lu, C., Cross, J. R., Morris, J. P., Shroff, A. S., . . . Lowe, S. W. (2013). Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. *Genes & Development, 27*(18), 1974-1985. doi: 10.1101/gad.226613.113

DiNardo, C. D., Propert, K. J., Loren, A. W., Paietta, E., Sun, Z. X., Levine, R. L., . . . Carroll, M. (2013). Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. *Blood, 121*(24), 4917-4924. doi: 10.1182/blood-2013-03-493197

Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., . . . Melnick, A. (2010). Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. *Cancer Cell, 18*(6), 553-567. doi: 10.1016/j.ccr.2010.11.015

Gross, Stefan, Cairns, Rob A., Minden, Mark D., Driggers, Edward M., Bittinger, Mark A., Jang, Hyun Gyung, . . . Mak, Tak W. (2010). Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. *The Journal of Experimental Medicine, 207*(2), 339.

Janin, M., Mylonas, E., Saada, V., Micol, J. B., Renneville, A., Quivoron, C., . . . de Botton, S. (2014). Serum 2-Hydroxyglutarate Production in IDH1- and IDH2-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. *Journal of Clinical Oncology, 32*(4), 297-+. doi: 10.1200/jco.2013.50.2047

Jin, G. L., Reitman, Z. J., Spasojevic, I., Batinic-Haberle, I., Yang, J. A., Schmidt-Kittler, O., . . . Yan, H. (2011). 2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP(+)-Dependent Isocitrate Dehydrogenase Mutations. *Plos One, 6*(2). doi: 10.1371/journal.pone.0016812

Kingsbury, J. M., Shamaprasad, N., Billmyre, R. B., Heitman, J., & Cardenas, M. E. (2016). Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability. *Human Molecular Genetics, 25*(16), 3524-3538. doi: 10.1093/hmg/ddw195

Lemonnier, F., Cairns, R. A., Inoue, S., Li, W. Y., Dupuy, A., Broutin, S., . . . Mak, T. W. (2016). The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. *Proceedings of the National Academy of Sciences of the United States of America, 113*(52), 15084-15089. doi: 10.1073/pnas.1617929114

Leonardi, R., Subramanian, C., Jackowski, S., & Rock, C. O. (2012). Cancer-associated Isocitrate Dehydrogenase Mutations Inactivate NADPH-dependent Reductive Carboxylation. *Journal of Biological Chemistry, 287*(18), 14615-14620. doi: 10.1074/jbc.C112.353946

Li, S. C., Chou, A. P., Chen, W. D., Chen, R. H., Deng, Y. Z., Phillips, H. S., . . . Lai, A. (2013). Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. *Neuro-Oncology, 15*(1), 57-68. doi: 10.1093/neuonc/nos261

Reitman, Z. J., Sinenko, S. A., Spana, E. P., & Yan, H. (2015). Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila. *Blood, 125*(2), 336-345. doi: 10.1182/blood-2014-05-577940

Robinson, G. L., Philip, B., Guthrie, M. R., Cox, J. E., Robinson, J. P., VanBrocklin, M. W., & Holmen, S. L. (2016). In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation. *Cancer Res Front, 2*(2), 311-329. doi: 10.17980/2016.311

Sellner, L., Capper, D., Meyer, J., Langhans, C. D., Hartog, C. M., Pfeifer, H., . . . von Deimling, A. (2010). Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations. *European Journal of Haematology, 85*(5), 457-459. doi: 10.1111/j.1600-0609.2010.01505.x

Showalter, M. R., Hatakeyama, J., Cajka, T., VanderVorst, K., Carraway, K. L., Fiehn, O., & Reproducibility Project: Cancer, Biology. (2017). Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Elife, 6*. doi: 10.7554/eLife.26030

Wen, H., Cho, H. R., Yun, T., Kim, H., Park, C. K., Lee, S. H., . . . Park, S. (2015). Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism. *Journal of Neurochemistry, 132*(2), 183-193. doi: 10.1111/jnc.12950

**Refuting:** NONE.

**Willingham 2012**

**Confirming:**

([Cioffi et al., 2015](#_ENREF_1); [Gholamin et al., 2017](#_ENREF_2); [Lee et al., 2014](#_ENREF_3); [Liu et al., 2015](#_ENREF_4); [Lo et al., 2015](#_ENREF_5); [Lo et al., 2016](#_ENREF_6); [Ngo et al., 2016](#_ENREF_7); [Sockolosky et al., 2016](#_ENREF_8); [Wang et al., 2013](#_ENREF_9); [Weiskopf et al., 2016](#_ENREF_10); [Weiskopf et al., 2013](#_ENREF_11); [Xiao et al., 2015](#_ENREF_12); [Yanagita et al., 2017](#_ENREF_13); [Yoshida et al., 2015](#_ENREF_14); [M. Zhang et al., 2016](#_ENREF_15); [X. Y. Zhang et al., 2017](#_ENREF_16))

Cioffi, M., Trabulo, S., Hidalgo, M., Costello, E., Greenhalf, W., Erkan, M., . . . Heeschen, C. (2015). Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. *Clinical Cancer Research, 21*(10), 2325-2337. doi: 10.1158/1078-0432.ccr-14-1399

Gholamin, S., Mitra, S. S., Feroze, A. H., Liu, J., Kahn, S. A., Zhang, M., . . . Cheshier, S. H. (2017). Disrupting the CD47-SIRP alpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. *Science Translational Medicine, 9*(381). doi: 10.1126/scitranslmed.aaf2968

Lee, T. K. W., Cheung, V. C. H., Lu, P., Lau, E. Y. T., Ma, S., Tang, K. H., . . . Ng, I. O. L. (2014). Blockade of CD47-Mediated Cathepsin S/Protease-Activated Receptor 2 Signaling Provides a Therapeutic Target for Hepatocellular Carcinoma. *Hepatology, 60*(1), 179-191. doi: 10.1002/hep.27070

Liu, X. J., Pu, Y., Cron, K., Deng, L. F., Kline, J., Frazier, W. A., . . . Xu, M. M. (2015). CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. *Nature Medicine, 21*(10), 1209-+. doi: 10.1038/nm.3931

Lo, J., Lau, E. Y. T., Ching, R. H. H., Cheng, B. Y. L., Ma, M. K. F., Ng, I. O. L., & Lee, T. K. W. (2015). Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. *Hepatology, 62*(2), 534-545. doi: 10.1002/hep.27859

Lo, J., Lau, E. Y. T., So, F. T. Y., Lu, P., Chan, V. S. F., Cheung, V. C. H., . . . Lee, T. K. W. (2016). Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma. *Liver International, 36*(5), 737-745. doi: 10.1111/liv.12963

Ngo, M., Han, A., Lakatos, A., Sahoo, D., Hachey, S. J., Weiskopf, K., . . . Boiko, A. D. (2016). Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived Xenografts. *Cell Reports, 16*(6), 1701-1716. doi: 10.1016/j.celrep.2016.07.004

Sockolosky, J. T., Dougan, M., Ingram, J. R., Ho, C. C. M., Kauke, M. J., Almo, S. C., . . . Garcia, K. C. (2016). Durable antitumor responses to CD47 blockade require adaptive immune stimulation. *Proceedings of the National Academy of Sciences of the United States of America, 113*(19), E2646-E2654. doi: 10.1073/pnas.1604268113

Wang, Y. H., Xu, Z. H., Guo, S. T., Zhang, L., Sharma, A., Robertson, G. P., & Huang, L. (2013). Intravenous Delivery of siRNA Targeting CD47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis. *Molecular Therapy, 21*(10), 1919-1929. doi: 10.1038/mt.2013.135

Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., . . . Sage, J. (2016). CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. *Journal of Clinical Investigation, 126*(7), 2610-2620. doi: 10.1172/jci81603

Weiskopf, K., Ring, A. M., Ho, C. C. M., Volkmer, J. P., Levin, A. M., Volkmer, A. K., . . . Garcia, K. C. (2013). Engineered SIRP alpha Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies. *Science, 341*(6141), 88-91. doi: 10.1126/science.1238856

Xiao, Z. Y., Chung, H. I., Banan, B., Manning, P. T., Ott, K. C., Lin, S., . . . Chapman, W. C. (2015). Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. *Cancer Letters, 360*(2), 302-309. doi: 10.1016/j.Canlet.2015.02.036

Yanagita, T., Murata, Y., Tanaka, D., Motegi, S. I., Arai, E., Daniwijaya, E. W., . . . Matozaki, T. (2017). Anti-SIRP alpha antibodies as a potential new tool for cancer immunotherapy. *Jci Insight, 2*(1). doi: 10.1172/jci.insight.89140

Yoshida, K., Tsujimoto, H., Matsumura, K., Kinoshita, M., Takahata, R., Matsumoto, Y., . . . Hase, K. (2015). CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer. *Cancer Medicine, 4*(9), 1322-1333. doi: 10.1002/cam4.478

Zhang, M., Hutter, G., Kahn, S. A., Azad, T. D., Gholamin, S., Xu, C. Y., . . . Cheshier, S. H. (2016). Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo. *Plos One, 11*(4). doi: 10.1371/journal.pone.0153550

Zhang, X. Y., Fan, J. J., Wang, S. F., Li, Y. B., Wang, Y. C., Li, S., . . . Ju, D. W. (2017). Targeting CD47 and Autophagy Elicited Enhanced Antitumor Effects in Non-Small Cell Lung Cancer. *Cancer Immunology Research, 5*(5), 363-375. doi: 10.1158/2326-6066.cir-16-0398

**Refuting:**

([Horrigan & Reproducibility Project Canc, 2017](#_ENREF_1); [Soto-Pantoja et al., 2014](#_ENREF_2))

Horrigan, S. K., & Reproducibility Project Canc, Biol. (2017). Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. *Elife, 6*. doi: 10.7554/eLife.18173

Soto-Pantoja, D. R., Terabe, M., Ghosh, A., Ridnour, L. A., DeGraff, W. G., Wink, D. A., . . . Roberts, D. D. (2014). CD47 in the Tumor Microenvironment Limits Cooperation between Antitumor T-cell Immunity and Radiotherapy. *Cancer Research, 74*(23), 6771-6783. doi: 10.1158/0008-5472.an-14-0037-t

**Sugahara 2010**

**Confirming:**

([Akashi et al., 2014](#_ENREF_1); [Li et al., 2015](#_ENREF_2); [Liu et al., 2017](#_ENREF_3); [Schmithals et al., 2015](#_ENREF_4); [Sugahara et al., 2015](#_ENREF_5))

Akashi, Y., Oda, T., Ohara, Y., Miyamoto, R., Kurokawa, T., Hashimoto, S., . . . Ohkohchi, N. (2014). Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1. *British Journal of Cancer, 110*(6), 1481-1487. doi: 10.1038/bjc.2014.49

Li, M. Q., Tang, Z. H., Zhang, D. W., Sun, H., Liu, H. Y., Zhang, Y., . . . Chen, X. S. (2015). Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models. *Biomaterials, 51*, 161-172. doi: 10.1016/j.biomaterials.2015.02.002

Liu, X. S., Lin, P., Perrett, I., Lin, J., Liao, Y. P., Chang, C. H., . . . Meng, H. (2017). Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. *Journal of Clinical Investigation, 127*(5), 2007-2018. doi: 10.1172/jci92284

Schmithals, C., Koberle, V., Korkusuz, H., Pleli, T., Kakoschky, B., Augusto, E. A., . . . Piiper, A. (2015). Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma. *Cancer Research, 75*(15), 3147-3154. doi: 10.1158/0008-5472.can-15-0395

Sugahara, K. N., Scodeller, P., Braun, G. B., de Mendoza, T. H., Yamazaki, C. M., Kluger, M. D., . . . Lowy, A. (2015). A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis. *Journal of Controlled Release, 212*, 59-69. doi: 10.1016/j.jconrel.2015.06.009

**Refuting:**

([Akashi et al., 2014](#_ENREF_1); [Mantis, Kandela, Aird, & Reproducibility Project Canc, 2017](#_ENREF_2); [Song et al., 2012](#_ENREF_3); [Sugahara et al., 2015](#_ENREF_4); [Zhang et al., 2015](#_ENREF_5))

Akashi, Y., Oda, T., Ohara, Y., Miyamoto, R., Kurokawa, T., Hashimoto, S., . . . Ohkohchi, N. (2014). Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1. *British Journal of Cancer, 110*(6), 1481-1487. doi: 10.1038/bjc.2014.49

Mantis, C., Kandela, I., Aird, F., & Reproducibility Project Canc, Biol. (2017). Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. *Elife, 6*. doi: 10.7554/eLife.17584

Song, W. T., Li, M. Q., Tang, Z. H., Li, Q. S., Yang, Y., Liu, H. Y., . . . Chen, X. S. (2012). Methoxypoly(ethylene glycol)-block-Poly(L-glutamic acid)-Loaded Cisplatin and a Combination With iRGD for the Treatment of Non-Small-Cell Lung Cancers. *Macromolecular Bioscience, 12*(11), 1514-1523. doi: 10.1002/mabi.201200145

Sugahara, K. N., Scodeller, P., Braun, G. B., de Mendoza, T. H., Yamazaki, C. M., Kluger, M. D., . . . Lowy, A. (2015). A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis. *Journal of Controlled Release, 212*, 59-69. doi: 10.1016/j.jconrel.2015.06.009

Zhang, W. Q., Yu, K. F., Zhong, T., Luo, L. M., Du, R., Ren, W., . . . Zhang, X. (2015). Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL? *Journal of Drug Targeting, 23*(10), 897-909. doi: 10.3109/1061186x.2015.1034279